"We are very much looking forward to supporting Anthera in their efforts to bring this novel, biotech-derived pancreatic enzyme replacement therapy to patients," shared Dr.
The RESULT clinical study design evolved from the data in the previous Sollpura trial (SOLUTION) and allows for more frequent and higher dose adjustments based upon clinical signs and symptoms. As with current practice with porcine enzymes, the RESULT study allows dose increases on an individualized basis to achieve maximum therapeutic benefit, while maintaining a potential reduction in daily pill burden due to Sollpura's significantly more compact formulation technology.
The Phase 3 RESULT study is designed to evaluate the non-inferiority of Sollpura at individualized doses compared to approved, porcine-derived, enteric-coated PERT when administered to patients with EPI due to CF. The study will enroll patients (N≈150) who are well-controlled on stable porcine PERT at screening, as demonstrated by the coefficient of fat absorption (CFA). The primary efficacy variable will evaluate the change from baseline in CFA following 4 weeks of treatment with either Sollpura or Pancreaze. Patients randomized to Sollpura will then be followed for an additional 20-Week extension period (total of 24 weeks on study) for longer term assessments of weight, height, BMI, and safety.
About Sollpura® (liprotamase)
Sollpura is a novel, non-porcine PERT containing a proprietary, biotechnology-derived formulation of cross-linked crystalline lipase, crystalline protease, and amorphous amylase with broad substrate specificity, formulated in a precise and fixed ratio to provide stability in acidic pH environments, like that found in the stomach, without enteric coating. Being non-porcine, liprotamase mitigates porcine-associated risks including supply limitations and the potential for contamination with pig-associated viral or other infectious agents. In addition, given its stability in the absence of enteric coating, a soluble, drinkable formulation of liprotamase is in development, which may provide an easy-to-administer option especially for pediatric patients and patients who receive their nutrition through feeding tubes.
Safe Harbor Statement
statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the
Contact Information Please contact Investor Relations at firstname.lastname@example.org
News Provided by Acquire Media